ZLDPF — Zealand Pharma A/S/ADR

OTC · Unknown · Unknown · CIK 2068427 · Denmark
Last close
$44.86
Market Cap
$3.10B
52W High
$55.36
52W Low
$38.50
ADV30
1,190
Next earnings
2026-05-07
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 34,000,000 34,000,000 -539,000,000 -394,000,000 15,301,000,000 3,849,000,000 832,000,000
Dec 2025 68,915,000 68,915,000 -356,544,000 -379,115,000 15,948,798,000 4,576,541,000 1,118,185,000
Sep 2025 49,569,000 49,569,000 -461,320,000 -404,233,000 16,797,246,000 5,972,711,000 1,634,645,000
Jun 2025 9,088,284,000 9,087,874,000 8,338,423,000 7,573,697,000 17,180,064,000 7,244,047,000 1,571,270,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$6,531,933,000
Investing CF
$-2,248,506,000
Financing CF
$-378,182,000
CapEx
$-69,073,000
Dividends Paid
Buybacks
$-345,566,000
EPS Diluted TTM
$91.34
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$6,287,000
Inventory
$0
Receivables
ST Investments
$10,532,267,000
EBIT TTM
$7,030,122,000
Pretax Income TTM
$7,001,063,000
Interest Exp TTM
$29,059,000
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$9,240,859,648
EBITDA
$6,799,047,168
Free Cash Flow
$4,224,191,744
Enterprise Value
$-10,884,188,160
Total Cash
$14,467,999,744
Total Debt
$414,000,000
Shares Out
69,089,276
Trailing EPS
$13.58
Book Value
$31.23
ROE
56.2%
ROA
34.7%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 9,214,860,000 7,113,523,000 6,455,008,000 15,948,798,000 1,118,185,000 6,531,933,000
Dec 2024 62,691,000 -1,269,071,000 -1,078,828,000 9,505,600,000 888,858,000 -930,816,000
Dec 2023 342,788,000 -577,217,000 -703,739,000 1,979,993,000 387,154,000 -425,668,000
Dec 2022 103,986,000 -816,599,000 -1,202,135,000 1,539,806,000 723,895,000 -942,311,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-1.16

Peers — same industry

TickerNameMarket CapLastDaily %
UTF COHEN & STEERS INFRASTRUCTURE FUND INC $3.09B $27.68
WRBY Warby Parker Inc. $3.11B $29.05
MGEE MGE ENERGY INC $3.09B $81.77
RCWLY Rockwool A/S/ADR $3.12B $32.00
SVYSF SOLVAY S A /ADR/ $3.03B $29.00

News headlines (Yahoo Finance, 1h cache)

Zealand Pharma (CPSE:ZEAL) Stock Stays Reasonable On Earnings Yet Richer On Fair Value
2026-07-08 04:31 · Yahoo
Zealand Pharma - Transactions related to share buy-back program (week 27, 2026)
2026-07-06 15:00 · Yahoo
Brenus Pharma Strengthens Its Governance With Designation of a New President and Appointment of Former Novo Nordisk EVP as Independent Member
2026-07-02 06:00 · Yahoo
Total number of shares and voting rights in Zealand Pharma as of June 30, 2026
2026-06-30 20:01 · Yahoo
Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.
2026-06-30 20:00 · Yahoo
Zealand Pharma - Transactions related to share buy-back program (week 26, 2026)
2026-06-29 15:00 · Yahoo
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
2026-06-22 20:00 · Yahoo
Zealand Pharma - Transactions related to share buy-back program (week 25, 2026)
2026-06-22 15:00 · Yahoo
[Latest] Global GLP-1 Receptor Agonist Market Size/Share Worth USD 95.3 Billion by 2035 at a 12.1% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Grow
2026-06-16 22:30 · Yahoo
Zealand Pharma - Transactions related to share buy-back program (week 24, 2026)
2026-06-15 15:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.